WVE WAVE Life Sciences

WAVE Life Sciences to Present at Upcoming Investor Conferences

WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will be participating at the following upcoming investor conferences:

  • Jefferies 2017 Global Healthcare Conference – WAVE Company Presentation

    Wednesday, June 7th at 1:30 P.M. ET – New York
  • The JMP Securities Life Science Conference – Company Panel Discussion: Neuromuscular Disorders

    Tuesday, June 20th at 2:00 P.M. ET – New York

A live webcast of the WAVE company presentation at the Jefferies 2017 Global Healthcare Conference will be available on the investor relations page of the WAVE Life Sciences corporate website at http://ir.wavelifesciences.com. A replay will remain archived on the corporate website for a limited time.

About WAVE Life Sciences

At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize rationally redesigned nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com.

EN
06/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

Yun Zhong
  • Yun Zhong

KOL Call Takeaways: WVE-006 Had A Good Start In AATD

Measuring Actual Outcomes Would be More Important. The level of protection required by each patient could be different. For some patients (e.g., those with more inflammation), a higher level (i.e., higher dose of augmentation therapy) could be required. Therefore, according to Dr. Hogarth, instead

David Nierengarten ... (+4)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
  • Yun Zhong

KOL Call Today @ 1PM ET: Just Breathe: Genetic Medicines in AATD

Dr. Hogarth completed his residency in internal medicine (1998-2001) and his fellowship in pulmonary and critical care medicine (2001-2004) before joining the University of Chicago faculty as an Assistant Professor of Medicine (2004-2014). He was later promoted to Associate Professor of Medicine (2

ResearchPool Subscriptions

Get the most out of your insights

Get in touch